Cardiology

Promoting adherence to a Mediterranean diet in children improves cardiometabolic health biomarkers, according to a new study.

A study showed participants with symptoms of anxiety and depression had significantly fewer controlled cardiovascular disease risk factors.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

Approximately 1454 counties with 2 million residents have no cardiologist in the US, primarily affecting rural and socioeconomically disadvantaged areas.

Our Cardiology Month in Review for June 2024 spotlights the pharmacotherapies making waves within the pipeline, the latest news in dyslipidemia, and updates in heart failure.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

A review of nearly 500 studies spanning more than 30 years details associations between weather events and cardiovascular risk.

The panelists stress the significance of a comprehensive approach to patient care, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

The panel explores issues surrounding medication adherence and the potential for improved patient engagement. They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.

The panel of medical experts addresses the challenges in raising awareness among healthcare providers about various medications and the need for increased awareness of the REDUCE-IT trial outcomes.

Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.

A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.

Erin Michos, MD, highlights several notable emerging lipid-lowering treatments, including bempedoic acid, the ANGPTL3 inhibitor evinacumab, the MTP inhibitor lomitapide, the ApoB-100 inhibitor mipomersen, and the ApoC-III degradation molecules volanesorsen and olezarsen.

Michael Koren, MD, discusses the recently released results from the VICTORIAN-INITIATE (V-INITIATE) trial, which were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session in Atlanta.

Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.

Malliett discusses the signs that a caregiver should refer to an HF specialist for advanced care options, including LVAD and heart transplant.

Fortman reviews the state of the 2021 AHA/ACC guideline recommendations to pursue shared decision making and cost-efficient testing strategies.

An AAPA 2024 session reflected on the joint AHA/ACC chest pain guidelines, particularly the adoption of high-density troponin level testing since 2021.

During AAPA 2024, a group of session presenters provide recommendations for the next year's agenda based on trends and development.

With incidence climbing amid climate change, an emergency medicine doctor has advice on prevention of cardiovascular and dermatologic effects.

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.